John MBA - Keros Therapeutics Senior Management

Keros Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.2817) % which means that it has lost $0.2817 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4382) %, meaning that it created substantial loss on money invested by shareholders. Keros Therapeutics' management efficiency ratios could be used to measure how well Keros Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2024. Return On Capital Employed is likely to drop to -0.52 in 2024. At this time, Keros Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 2.2 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 166.3 M in 2024.

Similar Executives

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Keros Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 97 people. Keros Therapeutics (KROS) is traded on NASDAQ Exchange in USA. It is located in 1050 Waltham Street, Lexington, MA, United States, 02421 and employs 160 people. Keros Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Keros Therapeutics Leadership Team

Keros Stock Performance Indicators

Additional Tools for Keros Stock Analysis